CN112601751B - 稠合噻吩化合物 - Google Patents

稠合噻吩化合物 Download PDF

Info

Publication number
CN112601751B
CN112601751B CN201980039027.2A CN201980039027A CN112601751B CN 112601751 B CN112601751 B CN 112601751B CN 201980039027 A CN201980039027 A CN 201980039027A CN 112601751 B CN112601751 B CN 112601751B
Authority
CN
China
Prior art keywords
compound
mmol
alkyl
amino
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980039027.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN112601751A (zh
Inventor
凯尔·W·H·程
阿帕瑞吉塔·荷思可特·克瑞西亚
保罗·E·艾德曼
方黎
法兰克·默库里奥
罗伯特·沙利文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayorsrix Co
Original Assignee
Bayorsrix Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayorsrix Co filed Critical Bayorsrix Co
Publication of CN112601751A publication Critical patent/CN112601751A/zh
Application granted granted Critical
Publication of CN112601751B publication Critical patent/CN112601751B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201980039027.2A 2018-06-13 2019-06-11 稠合噻吩化合物 Active CN112601751B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862684495P 2018-06-13 2018-06-13
US62/684,495 2018-06-13
PCT/US2019/036581 WO2019241271A1 (en) 2018-06-13 2019-06-11 Fused thiophene compounds

Publications (2)

Publication Number Publication Date
CN112601751A CN112601751A (zh) 2021-04-02
CN112601751B true CN112601751B (zh) 2024-04-02

Family

ID=67263033

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980039027.2A Active CN112601751B (zh) 2018-06-13 2019-06-11 稠合噻吩化合物

Country Status (8)

Country Link
US (2) US11191769B2 (https=)
EP (1) EP3807283A1 (https=)
JP (1) JP7365059B2 (https=)
CN (1) CN112601751B (https=)
AU (1) AU2019284605A1 (https=)
CA (1) CA3101335C (https=)
TW (1) TWI826463B (https=)
WO (1) WO2019241271A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513515B2 (en) * 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
AU2020387392B2 (en) 2019-11-19 2025-09-11 Bristol-Myers Squibb Company Compounds useful as inhibitors of Helios protein
WO2021155050A1 (en) * 2020-01-29 2021-08-05 Biotheryx, Inc. Kinase modulators, pharmaceutical compositions, and therapeutic applications
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
WO2022061348A1 (en) 2020-09-16 2022-03-24 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
CN116583509A (zh) * 2020-10-07 2023-08-11 上海睿跃生物科技有限公司 治疗癌症的化合物和方法
WO2022087335A1 (en) 2020-10-23 2022-04-28 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
TW202237580A (zh) 2020-12-14 2022-10-01 美商拜歐斯瑞克斯公司 Pde4降解劑、醫藥組合物及治療應用
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス， インコーポレイテッド イソインドリノン化合物
BR112023020077A2 (pt) 2021-04-06 2023-11-14 Bristol Myers Squibb Co Compostos de oxoisoindolina substituída por piridinila
WO2023069731A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications
WO2024015855A1 (en) 2022-07-13 2024-01-18 Monte Rosa Therapeutics, Inc. COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORS
CN120303264A (zh) 2022-09-09 2025-07-11 医诺康治疗公司 CK1α和双重CK1α/GSPT1降解化合物
WO2024222918A1 (zh) * 2023-04-28 2024-10-31 中国药科大学 一种苯并六元杂环类gspt1蛋白降解剂及其应用
CN119371398A (zh) * 2023-07-25 2025-01-28 安道麦阿甘有限公司 用于制备噻吩酮的新路线
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107073115A (zh) * 2014-08-22 2017-08-18 细胞基因公司 用免疫调节化合物与抗体组合治疗多发性骨髓瘤的方法
WO2018118947A1 (en) * 2016-12-21 2018-06-28 Biotheryx, Inc. Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1939922B (zh) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物
CN101186611B (zh) * 2006-11-15 2011-05-18 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用
AU2016266942B2 (en) * 2015-05-22 2018-10-18 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107073115A (zh) * 2014-08-22 2017-08-18 细胞基因公司 用免疫调节化合物与抗体组合治疗多发性骨髓瘤的方法
WO2018118947A1 (en) * 2016-12-21 2018-06-28 Biotheryx, Inc. Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.;Mary E. Matyskiela等;Journal of Medical Chemistry;第61卷(第61期);第535-542页 *

Also Published As

Publication number Publication date
US20220088025A1 (en) 2022-03-24
EP3807283A1 (en) 2021-04-21
JP2021527098A (ja) 2021-10-11
WO2019241271A1 (en) 2019-12-19
CA3101335C (en) 2024-01-09
TW202000674A (zh) 2020-01-01
AU2019284605A1 (en) 2020-12-10
CN112601751A (zh) 2021-04-02
US11191769B2 (en) 2021-12-07
US20200000814A1 (en) 2020-01-02
JP7365059B2 (ja) 2023-10-19
TWI826463B (zh) 2023-12-21
CA3101335A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
CN112601751B (zh) 稠合噻吩化合物
US11345714B2 (en) Compounds targeting proteins, compositions, methods, and uses thereof
US11400084B2 (en) Aminoamide compounds
US7030118B2 (en) Pyrrolotriazinone compounds and their use to treat diseases
US20170334932A1 (en) Chimeric compounds targeting proteins, compositions, methods, and uses thereof
ES2652648T3 (es) Moduladores P2X7
CA2694284A1 (en) Heterocyclic compounds useful as raf kinase inhibitors
CA3094988A1 (en) Thienopyrimidinone compounds
KR20180021820A (ko) Ido 억제제
PT1801108E (pt) Composto de morfolina para o tratamento de inflamações
CN109476653B (zh) 类视黄醇相关孤儿受体γ的杂芳族调节剂
CA3119886A1 (en) Heterocyclic spiro-compounds as am2 receptor inhibitors
HK40005345A (en) Heteroaromatic modulators of the retinoid-related orphan receptor gamma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant